Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
0.9350
+0.0872 (10.29%)
At close: May 30, 2025, 4:00 PM
0.9200
-0.0150 (-1.60%)
After-hours: May 30, 2025, 6:30 PM EDT
Invivyd Employees
As of December 31, 2024, Invivyd had 100 total employees, including 99 full-time and 1 part-time employees. The number of employees increased by 5 or 5.26% compared to the previous year.
Employees
100
Change (1Y)
5
Growth (1Y)
5.26%
Revenue / Employee
$366,880
Profits / Employee
-$1,427,180
Market Cap
112.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 5 | 5.26% |
| Dec 31, 2023 | 95 | 9 | 10.47% |
| Dec 31, 2022 | 86 | -17 | -16.50% |
| Dec 31, 2021 | 103 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
IVVD News
- 3 days ago - Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus - GlobeNewsWire
- 7 days ago - Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - GlobeNewsWire
- 9 days ago - Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 - GlobeNewsWire
- 15 days ago - Invivyd, Inc. (IVVD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 16 days ago - Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy - GlobeNewsWire
- 17 days ago - Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference - GlobeNewsWire
- 18 days ago - Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles - GlobeNewsWire